| Literature DB >> 32737973 |
Tamine T C Capato1, Nienke M de Vries2, Joanna IntHout3, Jordache Ramjith3, Egberto R Barbosa4, Jorik Nonnekes5, Bastiaan R Bloem2.
Abstract
OBJECTIVE: To fulfill the potential of nonpharmacological interventions for people with Parkinson disease (PD), individually tailored treatment is needed. Multimodal balance training supported by rhythmic auditory stimuli (RAS) can improve balance and gait in people with PD. The purpose of this study was to determine whether both freezers and nonfreezers benefit.Entities:
Mesh:
Year: 2020 PMID: 32737973 PMCID: PMC7596891 DOI: 10.1093/ptj/pzaa146
Source DB: PubMed Journal: Phys Ther ISSN: 0031-9023
Training Program Contents and Prescription of the Rhythmical Auditory Stimuli (RAS)-Supported Multimodal Balance Training, Regular Multimodal Training (Without RAS), and Control Intervention (Educational Program)
|
|
|
| |
|---|---|---|---|
|
|
|
|
|
| General content | Both interventions (RAS-supported multimodal balance training and regular multimodal training) consisted of 3 parts: balance, gait, and functional movements |
|
|
| Exercises involve 5 elements of posture, gait, and balance: | (a) Sensory integration (eg, walking tasks on varying surfaces) | ||
| Balance | Anticipatory postural adjustments (postural transitions, and multidirectional stepping, emphasizing movement velocity and amplitude) | Patients who did not show a good performance in Week 1 received additional instructions from a physical therapist in terms of how to perform the exercises correctly | Decreasing and increasing the base of support |
| Gait | Motor agility (eg, interlimb coordination under varying gait conditions and quick shifts of movement characteristic during predictable and unpredictable conditions) | Focusing on big steps, and visual cues | Increase environmental demands: uneven and narrow surfaces, spaces, doorways, varying bases of support, in multiple directions and turning |
| Functional movements | Performance at stability limits (controlled leaning tasks performed while standing with varying bases of support, stimulating weight shifts in multiple directions and turning) | Focusing attention on the most difficult part of the movement | Increase coordination demands; sit-to-stand, start-stop |
| Materials: Chairs, balls (65 cm, 55 cm, 30 cm); rubber bands (120 cm—medium density); sticks (100 cm), foams: 160 x 23 x 6 cm; 50 x 41 x 6 cm; 100 x 41 x 6 cm; 185 x 100 x 1.5 cm); bar, colored adhesive tapes; MA-1 KORG metronome. | |||
| Educational program | Contents of components were distributed in lectures, video sessions, general orientations about Parkinson disease and discussions | 45 min | |
| Lectures |
| 5 min—Welcome 30 min—Lecture 10 min—Discussion | |
| Video session |
| 5 min—Welcome 30 min—Video 10 min—Discussion | |
| Orientations and discussions |
| 5 min—Welcome 30 min—Orientations | |
Subgroup Participants’ Characteristics at Baseline Visit
|
|
| |||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| Age, y, mean [SD] | 74 [8] | 63 [13] | 76 [7] | 72 [9] | 68 [12] | 70 [10] |
| Sex, men, n (%) | 10 (55.6) | 9 (50) | 18 (81.8) | 16 (42.9) | 22 (78.6) | 11 (44) |
| H&Y grade, n (%) | ||||||
| I | 0 (0.0) | 0 (0.0) | 0 (0.0) | 12 (34.8) | 14 (39.4) | 7 (26) |
| II | 2 (11) | 3 (17.6) | 4 (18.2) | 11 (32.9) | 10 (30.3) | 6 (24) |
| III | 16 (88.9) | 14 (82.4) | 18 (72.7) | 10 (32.3) | 10 (30.3) | 12 (50) |
| Disease duration, y, median (IQT) | 8 (3–12) | 10 (4–16) | 10 (3–15) | 3 (2–8) | 5 (2–7) | 7 (1–10) |
| LEDD, mg/d, mean [SD] | 902 [514] | 889 [493] | 913 [457] | 563 [430] | 557[359] | 611 [324] |
| MMSE, score, mean [SD] | 26 [2] | 25 [2] | 24 [2] | 27 [2] | 25 [2] | 26 [2] |
| MoCA, score, mean [SD] | 25 [3] | 24 [2] | 23 [2] | 26 [3] | 24 [3] | 25 [3] |
| UPDRS 2, ADL score, mean [SD] | 19 [7] | 20 [8] | 23 [6] | 10 [6] | 12 [6] | 12 [6] |
| UPDRS 3, motor score, mean [SD] | 20 [7] | 23 [10] | 24 [7] | 13 [6] | 15 [6] | 17 [7] |
| Mini BESTest, mean (SE) | 11.0 (1.5) | 9.9 (1.6) | 11.8 (1.4) | 16.8 (1.1) | 21.4 (1.1) | 18.1 (1.4) |
| New Freezing of Gait Questionnaire, mean (SE) | 14.2 (1.3) | 21.0 (1.4) | 15.3 (1.2) | 0 (0) | 0 (0) | 0 (0) |
| Timed Up and Go Test, mean (SE) | 33.4 (3.5) | 28.5 (3.6) | 25.8 (3.2) | 18.4 (2.5) | 15.9 (2.7) | 18.9 (3.1) |
ADL = Activities of daily living; IQT = interquartile range; LEDD = levodopa equivalent daily dose; MMSE = Mini Mental Status Examination; MoCA = Montreal Cognitive Assessment; UPDRS = Unified Parkinson’s Disease Rating Scale; SD = standard deviation; SE = standard error
FigureMini-BESTest, New Freezing of Gait Questionnaire, and Timed Up and Go Test at each test visit. The blue line represents multimodal balance training supported by rhythmical auditory stimuli (RAS-supported), the dark-blue line represents multimodal balance training without RAS (regular), and the gray line represents the control intervention group. Error bars represent the 95% CIs.
Estimated Differences Between Baseline and Postintervention Measures With 95% CIs for Primary and Secondary Outcomes, for Freezers and Nonfreezers
|
|
| ||||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| |
| Mini BESTest | |||||||
| Freezers | Postintervention | 6.8 (5.2 to 8.3) | 2.5 (0.9 to 4.2) | −0.5 (−2.3 to 1.2) | |||
| 1-mo follow-up | 5.9 (4.4 to 7.5) | 1.8 (0.1 to 3.4) | −0.5 (−2.3 to 1.2) | −0. 8 (−0.7 to 0.0) | −0.7 (−1.6 to 0.2) | 0.0 (−0.9 to 0.9) | |
| 6-mo follow-up | 4.1 (2.5 to 5.6) | 0.8 (−0.8 to 2.4) | −0.4 (−2.3 to 1.3) | −2.7 (−3.9 to −1.5) | −1.7 (−3.0 to −0.4) | 0.0 (−1.2 to 1.4) | |
| Nonfreezers | Postintervention | 6.4 (5.2 to 7.5) | 3.2 (1.9 to 4.6) | −0.1 (−1.6 to 1.3) | |||
| 1-mo follow-up | 5.6 (4.4 to 6.7) | 1.5 (0.2 to 2.8) | −0.6 (−2.2 to 0.8) | −0.7 (−1.4 to −0.1) | −1.7 (−2.4 to −0.9) | −0.5 (−1.4 to 0.3) | |
| 6-mo follow-up | 4.2 (3.1 to 5.3) | 0.0 (−1.2 to 1.3) | −1.0 (−2.5 to 0.5) | −2.1 (−3.0 to −1.3) | −3.2(−4.2 to −2.2) | −0.8 (−2.0 to 0.3) | |
| New Freezing of Gait Questionnaire | |||||||
| Freezers | Postintervention | −1.5 (−3.3 to 0.2) | 0.0 (−2.4 to 2.5) | 0.5 (−1.8 to 2.8) | |||
| 1-mo follow-up | −1.4 (−3.1 to 0.3) | 0.7 (−1.8 to 3.2) | 1.5 (−0.8 to 3.8) | 7,7 (4.1 to 11.2) | 8.2 (4.7 to 11.7) | 7.0 (3.4 to 10.5) | |
| 6-mo follow-up | 0.0 (−1.7 to 1.7) | 1.1 (−1.4 to 3.6) | 1.5 (−0.8 to 3.8) | 3.6 (−0.0 to 7.3) | 4.4 (0.7 to 8.2) | 2.8 (−0.8 to 6.5) | |
| Nonfreezers | Postintervention | 0.9 (−0.6 to 2.4) | −0.2 (−1.9 to 1.4) | 2.1 (0.1 to 4.1) | |||
| 1-mo follow-up | 0.9 (−0.6 to 2.4) | 0.0 (−1.7 to 1.6) | 2.1 (0.1 to 4.1) | −1.7 (−4.6 to 1.2) | −1.6 (−4.6 to 1.3) | −2.0 (−5.0 to 0.9) | |
| 6-mo follow-up | 1.3 (−0.1 to 2.9) | 0.0 (−1.7 to 1.6) | 2.1 (0.1 to 4.1) | 0.3 (−2.8 to 3.6) | 0.3 (−2.9 to 3.5) | −0.1 (−3.3 to 3.1) | |
| Timed Up and Go Test | |||||||
| Freezers | Postintervention | −8.2 (−11.4 to −5.1) | −9.2 (−12.9 to −5.5) | 0.7 (−3.1 to 4.6) | |||
| 1-mo follow-up | −9.3 (−12.4 to −6.2) | −6.9 (−10.6 to −3.2) | 1.8 (−2.0 to 5.7) | 1.6 (−1.1 to 4.3) | 2.1 (−0.5 to 4.8) | 1.1 (−1.5 to 3.8) | |
| 6-mo follow-up | −7.3 (−10.5 to −4.2) | −6.0 (−9.7 to −2.3) | 2.2 (−1.6 to 6.1) | 2.0 (−0.5 to 4.7) | 2.9 (0.2 to 5.5) | 1.5 (−1.1 to 4.1) | |
| Nonfreezers | Postintervention | −4.3 (−7.2 to −1.6) | −3.9 (−6.8 to −1.0) | 0.8 (−2.6 to 4.3) | |||
| 1-mo follow-up | −5.1 (−7.8 to −2.4) | −3.2 (−6.1 to −0.2) | 0.7 (−2.7 to 4.2) | −1.1 (−3.2 to 0.9) | −1.0 (−3.1 to 1.0) | −1.4 (−3.5 to 0.6) | |
| 6-mo follow-up | −3.9 (−6.6 to −1.2) | −2.0 (−4.9 to 0.9) | 2.8 (−0.6 to 6.3) | 1.2 (−1.0 to 3.5) | 1.1 (−1.0 to 3.4) | 0.7 (−1.5 to 3.0) | |
LEDD = levodopa equivalent daily dose; MMSE = Mini Mental Status Examination; RAS = rhythmic auditory stimuli; UPDRS = Unified Parkinson’s Disease Rating Scale.
Group: Multimodal balance training supported by RAS (RAS-supported), multimodal balance training without RAS (regular), control intervention group (control).
Mini BEST: between-groups differences (95% CI) in improvement from baseline; adjusted for baseline MBEST, baseline LEDD, and baseline UPDRS 2 and 3. Mini BESTest—14 items, total 28 of points, scored 0-2 (higher score better balance).
New Freezing of Gait Questionnaire (NFOG): Adjusted NFOG mean difference (95% CI) from baseline. Adjusted for NFOG baseline, baseline LEDD, and baseline UPDRS 2 and 3.
Timed Up and Go Test (TUG): TUG—adjusted TUG mean difference (95% CI) from baseline. Adjusted for baseline TUG, baseline LEDD, baseline UPDRS 2 and 3. TUG was measured in time in seconds with a range from 5 to 60 s. A lower score means better mobility.
Observed Mean Values and Estimated Between-Group Differences in Improvement From Baseline and 95% CIs for Balance and Gait Outcomes for Freezers and Nonfreezers
|
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|---|
| Mini BESTest | |||||||
| Freezers | Baseline | 11.1 (7.8 to 14.3) | 11.7 (8.2 to 15.2) | 11.2 (7.8 to 14.5) | |||
| Postintervention | 18.4 (15.3 to 21.5) | 14.7 (10.8 to 18.4) | 11.2 (7.9 to 14.4) | 4.0 (2.0 to 6.5) | 7.3 (5.0 to 9.0) | 3.4 (0.7 to 5.0) | |
| 1-mo follow-up | 17.6 (14.0 to 21.2) | 13.9 (9.9 to 17.9) | 11.2 (7.8 to 14.5) | 4.1 (1.9 to 6.4) | 6.5 (4.2 to 8.8) | 2.3 (−0.1 to 4.7) | |
| 6-mo follow-up | 15.8 (12.0 to 19.5) | 12.9 (8.9 to 16.8) | 11.0 (11.3 to 20.3) | 3.2 (1.0 to 5.5) | 4.5 (2.2 to 6.9) | 1.3 (−1.0 to 3.6) | |
| Nonfreezers | Baseline | 16.7 (14.5 to 18.8) | 20.7 (17.8 to 23.6) | 17.0 (12.4 to 21.5) | |||
| Postintervention | 23.0 (21.0 to 25.0) | 23.3 (20.6 to 26.0) | 16.2 (12.3 to 21.1) | 3.1 (1.4 to 4.8) | 6.5 (4.7 to 8.4) | 3.4 (1.4 to 65.4) | |
| 1-mo follow-up | 22.4 (20.0 to 24.4) | 21.6 (18.4 to 24.3) | 17.2 (11.9 to 20.4) | 4.0 (2.3 to 5.7) | 6.3 (4.4 to 8.1) | 2.2 (0.2 to 4.2) | |
| 6-mo follow-up | 20.8 (18.7 to 23.0) | 20.0 (17.5 to 22.6) | 15.8 (11.3 to 20.3) | 4.2 (2.4 to 5.9) | 5.2 (3.4 to 7.1) | 1.0 (−0.9 to 3.0) | |
| New Freezing of Gait Questionnaire | |||||||
| Freezers | Baseline | 15.2 (12.2 to 18.2) | 20.4 (16.4 to 24.5) | 15.1 (12.1 to 18.2) | |||
| Postintervention | 12.2 (9.2 to 14.9) | 17.7 (14.7 to 20.6) | 15.1 (12.0 to 18.1) | 0.1 (−0.5 to 0.2) | −2.1 (−2.7 to −1.6) | −2.0 (−2.4 to −1.5) | |
| 1-mo follow-up | 12.9 (9.4 to 15.16) | 18.4 (15.6 to 21.2) | 16 (12.8 to 19.1) | −0.6 (−1.0 to −0.2) | −1.0 (−1.6 to −0.4) | −0.4 (−0.8 to 0.0) | |
| 6-mo follow-up | 14.2 (11.2 to 17.3) | 18.8 (16.3 to 21.4) | 16 (12.8 to 19.1) | −1.0 (−1.4 to −0.5) | −1.0 (−1.6 to −0.3) | −4.5 (−0.4 to 0.4) | |
| Nonfreezers | Baseline | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) | |||
| Postintervention | 2.3 (0.3 to 4.5) | 1.9 (0.3 to 3.4) | 3.7 (0.9 to 6.4) | −0.0 (−0.3 to 0.2) | −0.4 (−0.8 to −0.0) | −0.3 (−0.6 to −0.0) | |
| 1-mo follow-up | 2.3 (0.3 to 4.4) | 2.4 (0.3 to 3.7) | 3.6 (0.8 to 6.5) | −0.1 (−0.4 to 0.2) | −0.1 (−0.5 to 0.3) | −0.0 (−0.4 to 0.3) | |
| 6-mo follow-up | 2.7 (0.4 to 5.1) | 2.1 (0.4 to 3.8) | 3.6 (0.8 to 6.4) | 0.0 (−0.3 to 0.4) | 0.0 (−0.5 to 0.6) | 0.1 (−4.0 to 4.2) | |
| Timed Up and Go Test | |||||||
| Freezers | Baseline | 33.5 (23.9 to 43.1) | 27.0 (16.0 to 38.0) | 26.2 (17.0 to 35.4) | |||
| Postintervention | 21.9 (14.3 to 29.5) | 18.0 (10.3 to 25.8) | 27.1 (16.9 to 37.2) | 0.8 (−0.7 to 1.7) | 2.7 (1.4 to 3.9) | 1.8 (0.9 to 2.7) | |
| 1-mo follow-up | 21.4 (13.5 to 29.4) | 20.4 (12.7 to 28.0) | 28.3 (17.3 to 39.2) | 0.7 (−0.2 to 1.6) | 1.7 (0.4 to 3.0) | 1.0 (0.0 to 1.9) | |
| 6-mo follow-up | 23.7 (15.5 to 32.0) | 21.7 (13.5 to 29.0) | 29.0 (18.3 to 39.6) | 0.4 (−0.9 to 0.9) | 1.7 (0.4 to 3.0) | 1.0 (0.0 to 1.9) | |
| Nonfreezers | Baseline | 18.9 (14.9 to 22.8) | 14.6 (11.6 to 17.1) | 20.5 (12.5 to 28.5) | |||
| Postintervention | 14.6 (12.1 to 17.3) | 12.0 (9.7 to 12.3) | 21.1 (12.8 to 29.5) | 0.7 (0.1 to 1.4) | 2.1 (1.3 to 3.0) | 1.3 (0.7 to 2.0) | |
| 1-mo follow-up | 13.5 (11.5 to 15.4) | 12.8 (10.6 to 14.9) | 20.9 (12.7 29.1) | 1.7 (0.9 to 2.4) | 3.2 (2.2 to 4.2) | 1.5 (0.7 to 2.2) | |
| 6-mo follow-up | 14.6 (12.1 to 17.1) | 14.0 (11.9 to 16.7) | 22.8 (12.7 to 33.0) | 0.5 (−0.3 to 1.4) | 0.8 (−0.3 to 2.0) | 0.3 (−0.5 to 1.2) | |
LEDD = levodopa equivalent daily dose; MMSE = Mini Mental Status Examination; NFOG = New Freezing of Gait Questionnaire; RAS = rhythmical auditory stimuli; UPDRS = Unified Parkinson’s Disease Rating Scale.
Group: Multimodal balance training supported by RAS, multimodal balance training without RAS (regular), control intervention group (control).
Mini BEST: Between-group differences (95% CI) in improvement from baseline; adjusted for baseline Mini BESTest, baseline LEDD, and baseline UPDRS 2 and 3. Mini BESTest: 14 items, total 28 of points, scored 0–2 (higher score = better balance).
New Freezing of Gait Questionnaire (NFOG): Adjusted NFOG mean difference (95% CI) from baseline. Adjusted for NFOG baseline, baseline LEDD, baseline UPDRS 2 and 3.
Timed Up and Go Test (TUG): Adjusted TUG mean difference (95% CI) from baseline. Adjusted for baseline TUG, baseline LEDD, baseline UPDRS 2 and 3. TUG was measured in time in seconds with a range 5–60 s. A lower score means better mobility.